Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P330: Long-term outcomes following a switch from originator adalimumab to the biosimilar SB5 (Imraldi) in IBDECCO'21 Virtual
Year: 2021
Authors: Derikx, L.(1,2);Dolby, H.(2);Plevris, N.(2);Lucaciu , L.(2);Rees, C.(2);Lyons, M.(2);Siakavellas, S.(2);Constantine-Cooke, N.(3);Noble, C.(2);O’Hare, C.(2);Merchant, L.(2);Arnott, I.(2);Jones, G.R.(2,4);Lees, C.(2,5);
(1)Radboud University Nijmegen Medical Centre, Inflammatory Bowel Disease Centre- Department of Gastroenterology and Hepatology- Route 455, Nijmegen, The Netherlands;(2)Western General Hospital, Edinburgh IBD Unit, Edinburgh, United Kingdom;(3)University of Edinburgh- Western General Hospital, MRC Human Genetics Unit- Institute of Genetics and Molecular Medicine-, Edinburgh, United Kingdom;(4)University of Edinburgh, Centre for Inflammation Research- The Queen's Medical Research Institute, Edinburgh, United Kingdom;(5)University of Edinburgh- Western General Hospital, Centre for Genomics and Experimental Medicine- Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom
P331: The safety of tioguanine exposure during pregnancy: a case series of seventy-three pregnanciesECCO'21 Virtual
Year: 2021
Authors: Crouwel, F.(1);Simsek, M.(1);De Boer, M.A.(2);Mulder, C.J.J.(1);Buiter, H.J.C.(3);De Boer, N.K.(1);
(1)Amsterdam UMC- location VUmc, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC- location VUmc, Department of Obstetrics and Gynaecology, Amsterdam, The Netherlands;(3)Amsterdam UMC- location VUmc, Department of Radiology and Nuclear Medicine, Amsterdam, The Netherlands; On behalf of the tioguanine pregnancy study group and the Dutch Initiative on Crohn and Colitis (ICC)
P332: Population pharmacokinetics of ozanimod and active metabolite CC112273 in patients with ulcerative colitisECCO'21 Virtual
Year: 2021
Authors: Shen, J.(1);Tatosian, D.(1);Sid-Otmane, L.(2);Teuscher, N.(3);Chen, L.(1);Zhang, P.(1);Tirucherai, G.S.(1);Chitakara, D.(1);Marta, C.(1);
(1)Bristol Myers Squibb, Research and Development, Princeton, United States;(2)Certara USA- Inc., Integrated Drug Development, Montréal, Canada;(3)Certara USA- Inc., Integrated Drug Development, Raleigh, United States
P333: Endoscopic severity and CRP predict failure of medical rescue therapy in patients with acute severe ulcerative colitisECCO'21 Virtual
Year: 2021
Authors: Kakkadasam Ramaswamy, P.(1);Subhaharan, D.(1);Willmann, L.(1);Edwards, J.(1);Shukla, D.(1);Bhullar, M.(1);Moattar, H.(1);Dorrington, A.(1);Ishaq, N.(1);McIvor, C.(2);Mohsen, W.(1);
(1)Gold Coast University Hospital, Department of Digestive Health, Southport, Australia;(2)Logan Hospital, Department of Gastroenterology, Meadowbrook, Australia
P334: Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the Ulcerative Colitis clinical programmeECCO'21 Virtual
Year: 2021
Authors: Ungaro, R.C.(1);Ciorba, M.A.(2);Rogler, G.(3);Sharara, A.I.(4);Sunna, N.(5);Connelly, S.B.(6);Mundayat, R.(7);Lawendy, N.(6);Panés, J.(8);
(1)Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York- New York, United States;(2)Division of Gastroenterology, Washington University in St. Louis, St. Louis- Missouri, United States;(3)Department of Gastroenterology and Hepatology, University of Zürich, Zürich, Switzerland;(4)Division of Gastroenterology, American University of Beirut Medical Center, Beirut, Lebanon;(5)-, Pfizer Inc, Amman, Jordan;(6)Pfizer Inc, Collegeville, Pennsylvania, United States;(7)Pfizer Inc, New York, New York, United States;(8)Department of Gastroenterology, Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Barcelona, Spain
P335: Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: A KASID multicenter cohort studyECCO'21 Virtual
Year: 2021
Authors: Oh, K.(1);Hong, S.N.(2);Kim, E.S.(3);Na, S.Y.(4);Kang, S.B.(5);Koh, S.J.(6);Bang, K.B.(7);Jung, S.A.(8);Kim, K.O.(9);Choi, C.H.(10);Ye, B.D.(11);
(1)University of Ulsan College of Medicine- Asan Medical Center, Gastroenterology, Seoul, Korea- Republic Of;(2)Samsung Medical Center- Sungkyunkwan University School of Medicine, Medicine, Seoul, Korea- Republic Of;(3)Kyungpook National University School of Medicine, Internal Medicine, Daegu, Korea- Republic Of;(4)College of Medicine- Incheon St. Mary's Hospital- The Catholic University of Korea, Internal Medicine, Incheon, Korea- Republic Of;(5)College of Medicine- Daejeon St. Mary's Hospital- The Catholic University of Korea, Internal Medicine, Daejeon, Korea- Republic Of;(6)Seoul National University College of Medicine, Internal Medicine and Liver Research Institute, Seoul, Korea- Republic Of;(7)Dankook University College of Medicine, Internal Medicine, Cheonan, Korea- Republic Of;(8)Ewha Womans University School of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(9)Yeungnam University College of Medicine, Internal Medicine, Daegu, Korea- Republic Of;(10)Chung-Ang University College of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(11)University of Ulsan College of Medicine- Asan Medical Center, Gastroenterology and Inflammatory Bowel Disease Center, Seoul, Korea- Republic Of; IBD Research Group of the Korean Association for the Study of Intestinal Diseases
P336: Association between the prior duration of remission and efficacy outcomes in patients with Ulcerative Colitis treated with tofacitinib 10 mg twice daily who were in stable remission and either dose-reduced to tofacitinib 5 mg twice daily or remained on 10 mg twice daily: 6-month data from the double-blind, randomised RIVETING studyECCO'21 Virtual
Year: 2021
Authors: Dubinsky, M.C.(1);D’Haens, G.R.(2);Sandborn, W.J.(3);Ng, S.C.(4);Panés, J.(5);Su, C.(6);Lawendy, N.(6);Lazariciu, I.(7);Gardiner, S.(7);Mundayat, R.(7);Kulisek, N.(6);Modesto, I.(7);Torres, J.(8);
(1)Icahn School of Medicine at Mount Sinai, New York, New York, United States;(2)Department of Gastroenterology, Amsterdam University Medical Centres, Amsterdam, The Netherlands;(3)Division of Gastroenterology, University of California, San Diego- La Jolla- California, United States;(4)Institute of Digestive Disease- Department of Medicine and Therapeutics, LKS Institute of Health Science- Chinese University of Hong Kong, Hong Kong, Hong Kong- China;(5)Department of Gastroenterology, Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Barcelona, Spain;(6)Pfizer Inc, Collegeville, Pennsylvania, United States;(7)Pfizer Inc, New York, New York, United States;(8)Surgical Department- Gastroenterology Division, Hospital Beatriz Ângelo- Loures, and Faculdade de Medicina- Universidade de Lisboa- Lisbon, Portugal
P337: Early infliximab clearance predicts remission in children with Crohn’s DiseaseECCO'21 Virtual
Year: 2021
Authors: Chung, A.(1);Carroll, M.(1);Almeida, P.(1);Petrova, A.(1);Mould, D.(2);Wine, E.(1);Huynh, H.(1);
(1)University of Alberta, Faculty of Medicine and Dentistry, Edmonton, Canada;(2)Projections Research Inc, Pharmacology, Phoenixville, United States; Edmonton Pediatric IBD Clinic (EPIC)
P338: effectiveness and safety of biological therapies in elderly inflammatory bowel diseases patients results from a multi center study of GeteccuECCO'21 Virtual
Year: 2021
Authors: Suarez Ferrer, C.J.(1);Mesonero , F.(2);Caballol, B.(3);Saiz Chumillas, R.(4);Bastón-Rey, I.(5);Rubin de Celix, C.(6);Melcarne, L.(7);Caballero Mateos, A.(8);Calafat, M.(9);Alonso Galan, H.(10);Vega Villaamil, P.(11);Castro Senosiain, B.(12);Rodriguez Diaz, C.Y.(13);Plaza Santos, R.(14);Marques Cami, M.(15);Rodriguez Grau, M.C.(16);Ramirez, F.(17);Lopez-García, A.(18);Gomez Pastrana, B.(19);Gonzalez Partida, I.(20);Botella Mateu, B.(21);Cuevas del Campo, L.(22);Gonzalez Peña, E.(23);Iyo, E.(24);Elosua Gonzalez, A.(25);Sainz, E.(26);Hernandez, L.(27);Perez Galindo, P.(28);Rueda Garcia, J.L.(29);Martin-Arranz, M.D.(29);Lopez Sanroman, A.(30);Fernandez-Clotet, A.(3);Sicilia, B.(4);Calviño Suárez, C.(5);Mañosa Ciria, M.(9);Barreiro-De Acosta, M.(5);
(1)Hospital Universitario La Paz, GASTROENTEROLOGY DEPARTMENT, Madrid, Spain;(2)Ramón y Cajal University Hospital. Madrid, Gastroenterology Department-, Madrid, Spain;(3)Hospital Clinic of Barcelona, Gastroenterology department, Barcelona, Spain;(4)Burgos University Hospital, Gastroenterology department, Burgos, Spain;(5)Hospital Universitario Clínico de Santiago, Gastroenterology department, Santiago de compostela, Spain;(6)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP., Gastroenterology deparment, Madrid, Spain;(7)Hospital Universitari Parc Taulli, Gastroenterology Department, Sabadel- Barcelona, Spain;(8)Hospital Clinico San Cecilio, Gastroenterology department, Granada, Spain;(9)Hospital Germans Trias i Pujol, Gastroenterology department, Badalona, Spain;(10)Hospital Comarcal de Guipuzcua, Gastroenterology Department, Donostia, Spain;(11)Complexo Hospitalario Universitario de Ourense, Gastroenterology department, Ourense, Spain;(12)Hospital Universitario Marqués de Valdecilla. IDIVAL, Gastroenterology Department, Santander, Spain;(13)Hospital Universitario Nuestra Señora de la Candelaria, Gastroenterology Department, Tenerife, Spain;(14)Infanta Leonor University Hospital, Gastroenterology department, Madrid, Spain;(15)Hospital Arnau de Vilanova, Gastroenterology Department, Lleida, Spain;(16)Hospital del Henares, Gastroenterology Department, Coslada- Madrid, Spain;(17)Ciudad Real University Hospital, Gastroenterology Department, Ciudad Real, Spain;(18)Hospital del Mar, Gastroenterology Department, Barcelona, Spain;(19)General Hospital of Mataro, Gastroenterology Department, Maresme-Barcelona, Spain;(20)Hospital Universitario puerta de hierro, Gastroenterology department, Majadahonda-Madrid, Spain;(21)Hospital Univesitario Infanta Cristina, Gastroenterology department, Parla-Madrid, Spain;(22)Getafe University Hospital, Gastroenterology department, Getafe-Madrid, Spain;(23)Hospital Royo Villanova, Gastroenterology department, Zaragoza, Spain;(24)Hospital Comarcal de Inca, Gastroenterology Department, Baleares, Spain;(25)Hospital Garcia Orcoyen, Gastroenterology department, Estella-Navarra, Spain;(26)Hospital Xara Assistencial Althaia de Manressa, Gastroenterology Department, Barcelona, Spain;(27)Hospital Santos Reyes, Gastroenterology department, Aranda del duero-Burgos, Spain;(28)Pontevedra University Hospital Complex, Gastroenterology department, Pontevedra, Spain;(29)School of Medicine. Universidad Autónoma de Madrid. Hospital La Paz Institute forHealth Research- La Paz Hospita, Gastroenterology Department, Madrid, Spain;(30)Ramón y Cajal University Hospital, Gastroenterology deparment, Madrid, Spain; On behalf of the young GETECCU group
P339: Pregnant women with perianal Crohn’s Disease: suggestions for the improvement of the current guideline on delivery methodECCO'21 Virtual
Year: 2021
Authors: Schaafsma, I.(1);Hoogenboom, F.(2);Visschedijk, M.(1);Prins, J.(3);Dijkstra, G.(1);
(1)University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;(2)University Medical Center Groningen, Department of Surgery, Groningen, The Netherlands;(3)University Medical Center Groningen, Department of Gynecology, Groningen, The Netherlands
P340: Real-world treatment patterns and recurrence rates of rectovaginal fistulas in patients with Crohn’s disease: A retrospective cohort database analysisECCO'21 Virtual
Year: 2021
Authors: Karki, C.(1);Latremouille-Viau, D.(2);Gilaberte, I.(3);Hantsbarger, G.(4);Romdhani, H.(2);Lightner, A.(5);
(1)Takeda Pharmaceuticals USA- Inc., Global Evidence and Outcomes, Cambridge, United States;(2)Analysis Group- Inc., Analysis Group, Montreal, Canada;(3)Takeda Pharmaceuticals USA- Inc., Clinical Sciences, Cambridge, United States;(4)Takeda Pharmaceuticals USA- Inc., Statistical and Quantitative Sciences, Cambridge, United States;(5)Cleveland Clinic, Department of Colon and Rectal Surgery, Cleveland, United States
P340: Risankizumab in Inflammatory Bowel Disease: Real World Experience from a Pre-Approval Access ProgramECCO'22
Year: 2021
Authors: Dawson, P.(1);Sharma, E.(1);Dart, R.J.(1);Lim, S.(1);Anderson, S.H.(1);Ray, S.(1);Mawdsley, J.(1);Irving, P.M.(1);Samaan, M.A.(1);
(1)Guys and St Thomas NHS trust, Department of Gastroenterology, London, United Kingdom;
P341: Perceived risks and psychosocial burden during the COVID-19 pandemic in a large cohort of pediatric and adult patients with Inflammatory Bowel DiseaseECCO'21 Virtual
Year: 2021
Authors: Koletzko, L.(1);Klucker, E.(2);Le Thi, G.(2);Breiteneicher, S.(1);Rubio-Acero, R.(3);Neuhaus, L.(1);Stark, R.(4);Standl, M.(5);Hölscher, M.(3);Török, H.(1);Koletzko, S.(2,6);Schwerd, T.(2);
(1)LMU Klinikum, Department of Medicine II, Munich, Germany;(2)LMU Klinikum, Department of Pediatrics- Dr von Hauner Kinderspital, Munich, Germany;(3)LMU Klinikum, Division of Infectious Diseases and Tropical Medicine, Munich, Germany;(4)Helmholtz Zentrum München, Institute of Health Economics and Healthcare Management, Neuherberg, Germany;(5)Helmholtz Zentrum München, Institute of Epidemiology, Neuherberg, Germany;(6)University of Warmia and Mazury, Department of Pediatrics- Gastroenterology and Nutrition- School of Medicine Collegium Medicum, Olsztyn, Poland
P342: Correlation of the first lateral flow-based Point of Care test to quantify infliximab and anti-infliximab antibodies in a finger prick sample with the reference ELISA techniqueECCO'21 Virtual
Year: 2021
Authors: Ruiz-Argüello, M.B.(1);Pascual, J.(1);Del Río, L.(1);Urigoitia, A.(1);Balo Farto, C.(2);Fernández, C.(3);Mera, A.(2);De Toro, J.(3);Nagore, D.(1);Ametzazurra, A.(1);
(1)Progenika Biopharma - Grifols, Department of R&D, Derio, Spain;(2)Hospital Clínico Universitario de Santiago, Servicio Reumatología, Santiago de Compostela, Spain;(3)Complexo Hospitalario Universitario A Coruña, Servicio Reumatología, A Coruña, Spain
P343: Maintenance of deep remission in Crohn’s disease after switching from anti–TNF to ustekinumab.ECCO'21 Virtual
Year: 2021
Authors: Mantzaris, G.(1);Vraka, M.(1);Beka, H.(1);Georgiadi, T.(1);Albani, F.(1);Veretanos, C.(1);Mountaki, K.(1);Trikola, A.(1);Archavlis, E.(1);Christidou, A.(1);Manolakis, A.(1);Viazis, N.(1);Karampekos, G.(1);Philippidis, G.(1);Hatzievangelinou, C.(1);Tsatsa, A.(1);Georgiadou, A.(1);Panagopoulou, S.(1);
(1)Evaggelismos GHA, Gastroenterology, Athens, Greece
P344: Effectiveness and safety of switching patients with inflammatory bowel disease from originator infliximab to CT-P13: systematic review and meta-analysisECCO'21 Virtual
Year: 2021
Authors: Hanzel, J.(1,2);Strik, A.(2);Gecse, K.(2);D'Haens, G.(2);Dreesen, E.(3,4);
(1)University Medical Centre Ljubiljana, Department of Gastroenterology, Ljubljana, Slovenia;(2)Amsterdam UMC- AMC, Department of Gastroenterology, Amsterdam, The Netherlands;(3)KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(4)Uppsala University, Department of Pharmacy, Uppsala, Sweden
P345: Food-related quality of life in adults with Inflammatory Bowel Disease is influenced by restrictive eating behaviour, disease activity and surgery: a prospective multi-centre studyECCO'21 Virtual
Year: 2021
Authors: Day, A.(1,2);Yao, C.K.(3);Costello, S.(2,4);Andrews, J.(2,5);Bryant, R.(1,2);
(1)The Queen Elizabeth Hospital- Central Adelaide Local Health Network, Gastroenterology & Hepatology, Adelaide, Australia;(2)University of Adelaide, School of Medicine- Faculty of Health Sciences, Adelaide, Australia;(3)Monash University & Alfred Hospital, Translational Nutritional Sciences- Gastroenterology, Melbourne, Australia;(4)The Queen Elizabeth Hospital- Central Adelaide Local Health Network- School of Medicine- Faculty of Health Sciences- University of Adelaide, Gastroenterology & Hepatology, Adelaide, Australia;(5)Royal Adelaide Hospital- Central Adelaide Local Health Network, Gastroenterology & Hepatology, Adelaide, Australia
P346: Decreasing disparities in and use of systemic corticosteroid and disparities in use among paediatric patients with Crohn disease in a multicentre collaborativeECCO'21 Virtual
Year: 2021
Authors: Adler, J.(1);Kandavel, P.(2);Eder, S.(1);Saeed, S.(3);
(1)University of Michigan, Susan B. Meister Child Health Evaluation and Research Center, Ann Arbor, United States;(2)Children's Hospital of Los Angeles, Pediatric Gastroenterology, Los Angeles, United States;(3)Dayton Children's Hospital, Pediatric Gastroenterology, Dayton, United States; ImproveCareNow Network
P347: Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseasesECCO'21 Virtual
Year: 2021
Authors: Attauabi , M.(1,2,3);Höglund , C.(4);Fassov , J.(5);Pedersen , K.B.(6);Bansholm Hansen , H.(7);Wildt , S.(8);Dam Jensen , M.(9);Neumann , A.(10);Lind , C.(10);Albæk Jacobsen , H.(11);Popa , A.M.(12);Kjeldsen , J.(13);Pedersen , N.(14);Molazahi , A.(15);Haderselv , K.(16);Aalykke , C.(4);Knudsen , T.(6);Cebula , W.(12);Munkholm, P.(7);Bendtsen , F.(1,2);Seidelin , J.B.(3);Johan , B.(1,2);
(1)Copenhagen University Hospital, Gastrounit- Medical Section, Hvidovre, Denmark;(2)University of Copenhagen- Hvidovre Hospital, Copenhagen center for inflammatory bowel disease in children- adolescents and adults, Hvidovre, Denmark;(3)Herlev Hospital- University of Copenhagen, Department of Gastroenterology and Hepatology, Herlev, Denmark;(4)OUH Svendborg Hospital, Department of Medicine- Section of Gastroenterology, Svendborg, Denmark;(5)Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark;(6)Hospital of South West Denmark, Department of Medical Gastroenterology, Esbjerg, Denmark;(7)North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark;(8)Zealand University Hospital, Department of Medicine- Division of Gastroenterology, Koege, Denmark;(9)Lillebaelt Hospital, Department of Internal Medicine- Section of Gastroenterology, Vejle, Denmark;(10)Regional Hospital Viborg, Department of Internal Medicine, Viborg, Denmark;(11)Aalborg University Hospital, Department of Gastroenterology and Hepatology, Aalborg, Denmark;(12)Nykoebing Falster Hospital, Department of Medicine, Nykoebing Falster, Denmark;(13)OUH Odense University Hospital, Department of Medical Gastroenterology S, Odense, Denmark;(14)Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark;(15)Holbaek Hospital, Department of Internal Medicine, Holbaek, Denmark;(16)Rigshospitalet- Copenhagen University Hospital, Department of Gastroenterology, Copenhagen, Denmark
P348: Perception of cancer risk in inflammatory bowel disease-associated dysplasia and management practice is influenced by colonoscopy experience and workplace affiliation: results of an international clinician surveyECCO'21 Virtual
Year: 2021
Authors: Kabir, M.(1,2);Thomas-Gibson, S.(1,2);Hart, A.(2,3);Wilson, A.(1,2);
(1)St Mark's Hospital, Wolfson Endoscopy Unit, London, United Kingdom;(2)Imperial College London, Division of Surgery and Cancer, London, United Kingdom;(3)St Mark's Hospital, IBD Unit, London, United Kingdom